Similar articles

• [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].

  Guijarro C, Ruilope LM. Guijarro C, et al. Med Clin (Barc). 2015 Jul 20;145(2):67-9. doi: 10.1016/j.medcli.2015.04.007. Epub 2015 May 23. Med Clin (Barc). 2015. PMID: 26004275 Spanish. No abstract available.
• Cardiovascular endocrinology in 2012: PCSK9-an exciting target for reducing LDL-cholesterol levels.

  Betteridge DJ. Betteridge DJ. Nat Rev Endocrinol. 2013 Feb;9(2):76-8. doi: 10.1038/nrendo.2012.254. Epub 2013 Jan 8. Nat Rev Endocrinol. 2013. PMID: 23296165 Review.
• PCSK9 inhibition: the next statin?

  Vogel RA. Vogel RA. J Am Coll Cardiol. 2012 Jun 19;59(25):2354-5. doi: 10.1016/j.jacc.2012.03.011. Epub 2012 Mar 31. J Am Coll Cardiol. 2012. PMID: 22465426 No abstract available.
• [New drug development competition for LDL receptor].

  Fujita T. Fujita T. Nihon Yakurigaku Zasshi. 2014 May;143(5):262. doi: 10.1254/fpj.143.262. Nihon Yakurigaku Zasshi. 2014. PMID: 24813799 Japanese. No abstract available.
• New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

  Sahebkar A, Watts GF. Sahebkar A, et al. Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Clin Ther. 2013. PMID: 23932550 Review.